PUBLISHER: The Business Research Company | PRODUCT CODE: 1945436
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945436
Joint pain injections serve to reduce inflammation and discomfort, typically administered directly into the joint to alleviate pain. Joint pain is a common occurrence, particularly among the elderly or individuals with pre-existing medical conditions or disorders. Conditions such as arthritis, characterized by pain and inflammation, often contribute to joint pain. Joint pain injections offer a non-surgical approach to quickly relieve joint pain and inflammation.
The primary types of injections for joint pain include steroid joint injections, hyaluronic acid injections, platelet-rich plasma (PRP) injections, placental tissue matrix (PTM) injections, and various others. Steroid joint injections, also known as corticosteroid injections, are anti-inflammatory medications used to treat joint pain. They are particularly effective in reducing inflammation in individuals with conditions like rheumatoid arthritis and other forms of inflammatory arthritis. Joint pain injections are applied to various types of joints, including the hip joint, knee and ankle joints, shoulder and elbow joints, facet joints of the spine, and others. These injections are commonly distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs are influencing the joint pain injections market by increasing costs of imported biologics, syringes, processing equipment, and cold-chain packaging materials. Orthopedic clinics and hospitals in North America and Europe are most affected due to reliance on imported injectable formulations, while Asia-Pacific faces cost pressure on biologic production inputs. These tariffs are increasing treatment costs and limiting accessibility for some patients. However, they are also encouraging local biologics manufacturing, regional formulation development, and innovation in cost-efficient injectable therapies.
The joint pain injections market research report is one of a series of new reports from The Business Research Company that provides joint pain injections market statistics, including joint pain injections industry global market size, regional shares, competitors with a joint pain injections market share, detailed joint pain injections market segments, market trends and opportunities, and any further data you may need to thrive in the joint pain injections industry. This joint pain injections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The joint pain injections market size has grown rapidly in recent years. It will grow from $6.12 billion in 2025 to $6.89 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing prevalence of arthritis and joint disorders, aging global population, rising demand for minimally invasive pain treatments, growing awareness of regenerative therapies, expansion of orthopedic specialty care.
The joint pain injections market size is expected to see rapid growth in the next few years. It will grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of biologic pain therapies, rising focus on personalized medicine, expansion of sports injury management, growing investments in regenerative medicine, increasing preference for non-opioid pain management. Major trends in the forecast period include increasing adoption of non-surgical pain management therapies, rising use of hyaluronic acid and prp injections, growing demand for personalized pain treatment approaches, expansion of regenerative medicine-based injections, enhanced focus on outpatient pain relief solutions.
The increasing prevalence of arthritis and musculoskeletal disorders is expected to drive growth of the joint pain injections market. Musculoskeletal disorders represent the leading cause of disability globally, with low back pain being the most common cause of impairment across 160 countries. Patients increasingly rely on injections for pain management and treatment of inflammatory conditions. For example, in August 2023, the Institute for Health Metrics and Evaluation (IHME), a U.S.-based independent health research organization, reported that nearly one billion people are projected to be living with osteoarthritis by 2050. Therefore, the growing burden of arthritis and musculoskeletal disorders is fueling demand in the joint pain injections market.
Leading companies in the joint pain injections market are concentrating on developing innovations such as single-injection formulations, which prioritize patient convenience. A single-injection formulation is a type of drug delivery system designed to deliver a specific dose of medication in a single injection, offering sustained therapeutic effects over an extended period without the need for multiple doses. For example, in July 2024, LG Chem Ltd., a chemicals company based in South Korea, introduced Synovian, a new treatment for knee osteoarthritis in China that features a convenient single-injection formulation, making it the first of its kind in the country. The product aims to capture a significant market estimated at around KRW 200 billion (approximately USD 150 million). Developed using proprietary technology, it demonstrates innovation in meeting patient needs, focusing on providing effective relief with minimal administration effort.
In July 2025, Johnson & Johnson MedTech, a U.S.-based provider of medical devices and healthcare solutions, partnered with Pacira BioSciences to expand early-intervention options for knee osteoarthritis. Through this collaboration, both companies aim to increase market adoption of ZILRETTA(TM), a triamcinolone acetonide extended-release injectable, improve product accessibility, and strengthen presence in the knee osteoarthritis segment. Pacira BioSciences is a U.S.-based specialty pharmaceutical company that develops and commercializes non-opioid pain management and local analgesic products, including intra-articular injections for joint pain.
Major companies operating in the joint pain injections market are Seikagaku Corporation, Anika Therapeutics Inc., Bioventus Inc., Flexion Therapeutics Inc., Ferring Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Limited, Wockhardt Ltd., Mallinckrodt Pharmaceuticals Ltd., Mylan N.V., Bayer AG, Eli Lilly and Company, Ipsen SA, Takeda Pharmaceutical Company Limited, AstraZeneca plc
North America was the largest region in the joint pain injections market in 2025. The regions covered in the joint pain injections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the joint pain injections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The joint pain injections market consists of sales of epidural steroid injections, facet joint injections, viscosupplementation injections, corticosteroid injections and hyaluronic acid injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Joint Pain Injections Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses joint pain injections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for joint pain injections ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The joint pain injections market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.